Nano Nuclear Energy Inc. — Form 10-Q Summary
Reporting period: Fiscal quarter and six months ended March 31, 2024; comparative periods ended March 31, 2023. The company’s fiscal year ends September 30. Financial statements are unaudited.
Business context
Nano Nuclear is an early-stage, pre-revenue company developing portable microreactors ZEUS and ODIN, a domestic HALEU fuel fabrication business, HALEU transportation technology, and nuclear consulting services. It reported no revenue through March 31, 2024.
Financial results and liquidity
| Metric | Three months ended Mar. 31, 2024 | Three months ended Mar. 31, 2023 | Six months ended Mar. 31, 2024 | Six months ended Mar. 31, 2023 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Research and development | $290,539 | $392,900 | $810,555 | $520,606 |
| General and administrative | $1,423,309 | $1,127,534 | $2,252,205 | $1,683,973 |
| Operating loss | $1,713,848 | $1,520,434 | $3,062,760 | $2,204,579 |
| Net loss | $1,677,628 | $1,520,434 | $2,991,573 | $2,204,579 |
| Basic and diluted loss per share | $0.07 | $0.07 | $0.13 | $0.10 |
Margins are not meaningful because the company had no revenue. For the six months, operating cash outflow was $3.409 million, compared with $1.469 million a year earlier. Financing provided $2.411 million, primarily from common-stock issuances. Cash declined by $998,000 to $5.955 million.
At March 31, 2024, working capital was $5.985 million, total assets were $8.870 million, and stockholders’ equity was $6.636 million. Total liabilities were $2.234 million, principally operating lease liabilities of $1.910 million; the filing reports no borrowings. The company had a $1.909 million present-value lease obligation, including $281,000 current and $1.629 million long-term.
Changes and notable items
- Quarterly R&D expense fell 26%, primarily because there was no R&D equity compensation in the 2024 quarter versus $125,450 in the prior-year quarter. Six-month R&D rose 56% as development activity increased.
- G&A rose 26% for the quarter and 34% for the six-month period, attributed mainly to additional office and staff costs. The company also expects higher public-company compliance costs after its IPO.
- Advertising expense was approximately $435,000 for the quarter and $609,000 for the six months, compared with approximately $159,000 and $178,000 in the respective prior-year periods.
- In March, a subscriber terminated a put right over 2 million shares, and $5.0 million was reclassified from mezzanine equity to stockholders’ equity.
- After quarter-end, the May 2024 IPO issued 2,562,500 shares at $4.00, generating approximately $9.0 million in net proceeds. The underwriter subsequently exercised its full over-allotment option, adding approximately $1.415 million net. These proceeds were not included in March 31 cash.
Outlook, risks, and contingencies
Management estimated approximately $4 million of spending over the next 12 months for microreactor development and related costs. It estimated microreactor demonstration work during 2024–2026, licensing during 2026–2031, and launch during 2030–2031. It also anticipated beginning consulting services by the end of 2024, through acquisition or, if unsuccessful, internal development requiring about $1 million over 12 months. These are estimates, not assured milestones or formal financial guidance.
Management said available working capital should cover liabilities and commitments for at least 12 months after issuance of the statements, while also expecting to raise additional equity to execute its long-term strategy. Key risks include sustained operating losses and funding needs; design, demonstration, manufacturing, and commercial execution; lengthy and uncertain NRC and other regulatory approvals; HALEU sourcing and facility development; and the ability to acquire or establish a consulting business. The company disclosed no material legal proceedings and no material subsequent events other than the IPO and over-allotment. Management concluded disclosure controls were effective and reported no material change in internal control over financial reporting.
Important facts for investors to verify
- Whether IPO and over-allotment proceeds, and subsequent cash use, provide adequate funding against the company’s development plans and ongoing burn rate.
- Progress and costs for ZEUS and ODIN demonstration work, fuel-facility development, licensing, and transportation plans against management’s estimated timelines.
- Whether consulting-service acquisition discussions result in a definitive transaction or the company proceeds with its estimated internal build-out.
- Future revenue, operating expenses, dilution, and financing needs; the company remained pre-revenue and reported an accumulated deficit of $10.274 million at March 31, 2024.